Intercytex Group

Intercytex Group plc is a development-stage biotechnology company focused on the research, development, and commercialization of cell therapies for skin and hair repair and regeneration. The company leverages its integrated cell technology platform to develop living products based on human cells. Its product pipeline includes: VAVELTA, a facial rejuvenation and skin damage repair product that has completed phase II trials; SHEF-1-stem cell line, which is being developed as a treatment for AMD, the leading cause of blindness in the elderly; ICX-TRC, a hair regeneration product that has completed phase II trials; and ICX-SKN, a skin graft alternative for burns and acute wounds that has completed phase I trials. The company was founded in 2000 and is headquartered in Cambridge, UK.